WallStSmart

FibroBiologics, Inc. Common Stock (FBLG)vsRevolution Medicines Inc (RVMD)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

RVMD leads profitability with a 0.0% profit margin vs 0.0%. FBLG earns a higher WallStSmart Score of 25/100 (F).

FBLG

Avoid

25

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 5.5
Piotroski: 2/9Altman Z: -12.57

RVMD

Avoid

23

out of 100

Grade: F

Growth: 3.7Profit: 2.5Value: 6.7Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for FBLG.

RVMDUndervalued (+89.8%)

Margin of Safety

+89.8%

Fair Value

$1883.88

Current Price

$166.87

$1717.01 discount

UndervaluedFair: $1883.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FBLG1 strengths · Avg: 10.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.279/10

Conservative balance sheet, low leverage

Areas to Watch

FBLG4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$6.57M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
15.0x4/10

Trading at 15.0x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : FBLG

The strongest argument for FBLG centers on Price/Book.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : FBLG

The primary concerns for FBLG are Revenue Growth, EPS Growth, Market Cap.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

FBLG carries more volatility with a beta of 1.84 — expect wider price swings.

FBLG is growing revenue faster at 0.0% — sustainability is the question.

FBLG generates stronger free cash flow (-3M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

FBLG scores higher overall (25/100 vs 23/100). RVMD offers better value entry with a 89.8% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

FibroBiologics, Inc. Common Stock

HEALTHCARE · BIOTECHNOLOGY · USA

FibroBiologics, Inc. is an innovative biotechnology company dedicated to advancing regenerative medicine through its proprietary fibroblast cell technology, specifically targeting degenerative diseases and spinal disorders. The company's robust intellectual property portfolio and commitment to clinical excellence position it favorably within the rapidly evolving cellular therapy market. By fostering strategic partnerships and enhancing research initiatives, FibroBiologics aims to transform patient care and improve clinical outcomes with its cutting-edge therapeutic solutions.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?